Duloxetine Inhibits Microglial P2X4 Receptor Function and Alleviates Neuropathic Pain after Peripheral Nerve Injury

Tomohiro Yamashita¹, Shota Yamamoto², Jiaming Zhang¹, Miho Kometani¹, Daisuke Tomiyama¹, Keita Kohno², Hidetoshi Tozaki-Saitoh¹,², Kazuhide Inoue¹,* Makoto Tsuda¹,²*

¹ Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan, ² Department of Life Innovation, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

Abstract

P2X4 receptors (P2X4R) are a family of ATP-gated non-selective cation channels. We previously demonstrated that activation of P2X4R in spinal microglia is crucial for neuropathic pain, a highly debilitating chronic pain condition, suggesting that P2X4R is a potential therapeutic target for treating neuropathic pain. Thus, the identification of a compound that has a potent inhibitory effect on P2X4R is an important clinical challenge. In the present study, we screened a chemical library of clinically approved drugs and show for the first time that duloxetine, a serotonin and noradrenaline reuptake inhibitor, has an inhibitory effect on rodent and human P2X4R. In primary cultured microglial cells, duloxetine also inhibited P2X4R-, but not P2X7R-, mediated responses. Moreover, intrathecal administration of duloxetine in a model of neuropathic pain produced a reversal of nerve injury-induced mechanical allodynia, a cardinal symptom of neuropathic pain. In rats that were pretreated with a serotonin-depleting agent and a noradrenaline neurotoxin, the antiallodynic effect of duloxetine was reduced, but still remained. Based on these results, we suggest that, in addition to duloxetine’s primary inhibitory action on serotonin and noradrenaline transporters, an inhibitory effect on P2X4R may be involved at least in part in an antiallodynic effect of intrathecal duloxetine in a model of neuropathic pain.

Introduction

Neuropathic pain is a source of intractable chronic pain in conditions such as cancer, fibromyalgia, diabetic neuropathy and postherpetic neuralgia. A prominent symptom is abnormal pain hypersensitivity evoked by normally innocuous stimuli, known as mechanical allodynia. Analgesics such as pregabalin and opioids are used for treating neuropathic pain, however it has been estimated that only one in four patients experiences over 50% pain relief [1]. Furthermore, the clinical use of these drugs is often limited by side effects such as dizziness, obstipation.
Duloxetine Inhibits P2X4 Receptor Function

Competing Interests: Makoto Tsuda has received a research grant from Eli Lilly Japan and does not have any other competing interests (relating to employment, consultancy, patents, products in development, marketed products, etc.) to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. The other authors have no conflict of interest to declare.

and nausea [2]. Thus, there is a need to explore and develop analgesics with therapeutic potential for neuropathic pain.

Microglia are the resident immune cells in the central nervous system [3]. Following peripheral nerve injury (PNI), microglia critically contribute to the pathogenesis of neuropathic pain [4,5,6,7,8]. We have previously shown that the purinergic receptor P2X4 (P2X4R), a subtype of ATP-gated non-selective cation channels, is highly upregulated in spinal microglia after PNI, and blocking the function of the P2X4R produces a reversal of mechanical allodynia [4]. Furthermore, disruption of the P2X4R gene abolishes mechanical allodynia induced by PNI [9,10]. Interfering with microglial P2X4R upregulation by inhibiting interferon regulatory factor 8 and 5 also suppresses PNI-induced allodynia [6,7]. These findings indicate that activation of P2X4R in spinal microglia plays a pivotal role in the pathogenesis of neuropathic pain and suggest that P2X4R blockers are a promising therapeutic approach for neuropathic pain [11,12].

The aim of this study was to identify clinically approved drugs that inhibit P2X4R. In a recent small scale screening of clinically approved antidepressants and anticonvulsants, we showed that paroxetine, a selective serotonin (5-HT) reuptake inhibitor (SSRI), has an inhibitory effect on P2X4R and produces an antiallodynic effect in an animal model of neuropathic pain [13]. In this study, we performed a large scale screening of a chemical library (1979 clinically approved compounds) to identify a drug with a more potent inhibitory effect on P2X4R than paroxetine, and tested the effects in an animal model of neuropathic pain.

We found that duloxetine, a 5-HT and noradrenaline (NA) reuptake inhibitor (SNRI), has an inhibitory effect on the function of microglial P2X4R. Furthermore, intrathecal duloxetine attenuated PNI-induced mechanical allodynia, an effect that remained even in rats that had been pretreated with the 5-HT depleting agent parachlorophenylalanine (PCPA) and the NA neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). Therefore, it is possible that, in addition to duloxetine's inhibition of 5-HT and NA transporters, inhibition of P2X4R may be involved in its antiallodynic effect in a model of neuropathic pain.

Materials and Methods

Reagents

Reagents were obtained from the following sources: adenosine 5'-triphosphate disodium salt (ATP), 2'(3')-O-(4-Benzoylbenzoyl)adenosine 5'-triphosphate triethylammonium salt (BzATP), adenosine 5'-diphosphate sodium salt (ADP), amitriptyline hydrochloride, buproprion hydrochloride, clomipramine hydrobromide, maprotiline hydrochloride, mirtazapine, ivermectin, 4-Chloro-DL-phenylalanine methyl ester hydrochloride (PCPA), and N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) from Sigma-Aldrich (St. Louis, MO, USA); Fura-2-AM from Dojindo (Kumamoto, Japan); duloxetine hydrochloride and paroxetine hydrochloride from Toronto Research Chemicals (Toronto, Canada); pyridoxal phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) tetrasodium salt from Tocris Bioscience (Bristol, UK). The approved drugs library of 1979 compounds were provided in the form of 96-well plate format by Drug Discovery Initiative, DDI, The University of Tokyo (Tokyo, Japan).

Cell cultures

1321N1 human astrocytoma cells stably expressing rat (r) P2X4R, rP2X7R and human (h) P2X4R were used. Cells were maintained in low-glucose DMEM supplemented with 10% heat-inactivated FBS, penicillin and streptomycin in a humidified atmosphere of 5% CO₂ at 37°C. Primary cultured microglia were prepared according to a previously described method [14,15]. In brief, the mixed glial culture was prepared from brain of neonatal Wistar rats (Kyudo, Saga, Japan) and maintained for 9–24 days in DMEM with 10% heat-inactivated FBS. The mouse
microglial cell line C8-B4 cells were maintained in high-glucose DMEM with 4 mM GlutaMax supplemented with 10% heat-inactivated FBS, penicillin and streptomycin in a humidified atmosphere of 5% CO₂ at 37°C.

Animals

Male Wistar rats (250–270 g; Japan SLC, Shizuoka, Japan) were housed in individual cages. Neonatal Wistar rats (Kyudo, Saga, Japan) were used for experiments in primary cultured microglia. The animals were housed in groups of four per cage with wooden chip on the floor during habituation, and then in individual cages after intrathecal catheterization under controlled temperature (22 ± 1°C) and humidity (55 ± 10%). The room was lighted from 8:00 AM to 8:00 PM. Food and water were freely available. Standard food (Clea Japan, Tokyo, Japan) and tap water were freely available. The physical conditions of the animals were carefully monitored every other day during the animal experiments. In this study, no animals became ill or died prior to the experimental endpoint. All animals utilized in this study were euthanized by means of i.p. injection of pentobarbital after experiments. All animal experiments were conducted according to the national and international guidelines contained in the 'Act on Welfare and Management of Animals' (Ministry of Environment of Japan) and 'Regulation of Laboratory Animals' (Kyushu University) and under the protocols approved by the Institutional Animal Care and Use committee review panels at Kyushu University.

Measurement of Ca²⁺ responses in 96-well plates (FDSS 7000EX system)

Measurement of Ca²⁺ imaging in 96-well plates was performed using the Functional Drug Screening System 7000EX (FDSS7000EX, Hamamatsu, Japan). 1321N1 cells stably expressing rat P2X4R and rat P2X7R were cultured for 24 h at 37°C on 96-well plates (2.0 × 10⁴ cells/well). Cells were loaded with 2.5 μM Fura-2-AM containing 0.02% pluronic (Molecular Probes) in a balanced salt solution (BSS; 150 mM NaCl, 5 mM KCl, 1.8 mM CaCl₂, 1.2 mM MgCl₂, 10 mM D-glucose and 25 mM HEPES, pH 7.4) at room temperature for 45 min and then washed with BSS. After pretreatment with the test drugs for 10 min, cells were stimulated with 10 μM ATP or 100 μM BzATP.

Measurement of Ca²⁺ responses in single cells (single cells analysis)

Measurement of Ca²⁺ responses in single cells were assessed by ratiometric images (F340/F380) of Fura-2 fluorescence, which were detected with Aquacosmos/HiSca (Hamamatsu Photonics, Hamamatsu, Japan). 1321N1 cells stably expressing human P2X4R were transferred to poly-L-lysine-coated glass coverslips, placed in silicon rubber walls (Flexiperm, Greiner Bio-One GmbH, Frickenhausen, Germany) (1.0 × 10⁴ cells /well). 1321N1 cells were cultured for 24 h at 37°C and loaded with 2.5 μM Fura-2-AM in BSS at room temperature for 45 min. Rat microglial cells were obtained as floating cells over the mixed glial culture. The floating cells were collected by gentle shaking and transferred to poly-L-lysine-coated glass coverslips, placed in Flexperim (5.0 × 10⁶ cells/well). Microglial cells were cultured for 3–6 h and were loaded with 5 μM Fura-2-AM in DMEM at 37°C for 30 min. Then, the cells were washed with BSS and mounted on an inverted fluorescence microscope (ECLIPSE TE2000-U; Nikon, Tokyo, Japan) equipped with a Xenonlamp (Xe75W; Nikon). Data were calculated using the relative increase ratio (F340/F380) from the basal level prior to ATP application with or without duloxetine. The effects of duloxetine were evaluated by the S2 (2nd [Ca²⁺], response) / S1 (1st [Ca²⁺], response), where [Ca²⁺] represents intracellular Ca²⁺ concentration, or the ratio of the fluorescence intensity (F340/F380). Following addition of nucleotides (10, 50 or 100 μM...
ATP, 100 μM BzATP, or 10 μM ADP) for 30 s, the cells were pretreated with duloxetine for 10 min. The cells were pre-incubated with ivermectin (3 μM) for 3 min prior to ATP application.

Intrathecal administration
Under isoflurane (2% [v/v]) anesthesia, a 32-gauge intrathecal catheter (ReCathCo, Allison Park, PA) for intrathecal administration of duloxetine (20 and 50 μg/20 μL) was inserted through the atlanto-occipital membrane into the lumbar enlargement and externalized through the skin according to a method described previously [5,16].

Neuropathic pain model and behavioral test
We used the spinal nerve injury model [17] with some modifications. A unilateral L5 spinal nerve of rats was tightly ligated and cut just distal to the ligature under isoflurane (2.5%) anesthesia. To assess mechanical allodynia, calibrated von Frey filaments (0.4–15 g, Linton Instrumentation, Diss, Norfolk, UK) were applied to the plantar surface of the hindpaw from below the mesh floor. The 50% paw-withdrawal threshold (PWT) was determined by the up-down method [18]. Duloxetine (20 or 50 μg/20 μl) or vehicle (Phosphate buffered saline, 20 μl) was intrathecally administered to rats 7 days after PNI and mechanical allodynia was measured for 300 min. The paw withdrawal threshold at 180 min after intrathecal administration of duloxetine was converted into antiallodynic effect (%) which was calculated by the formula: antiallodynic effect (%) = 100 × (test value−control value)/(15 g−control value). Control and test values were paw withdrawal threshold at 0 and 180 min, respectively. PCPA (300 mg/kg, an inhibitor of 5-HT synthesis) was intraperitoneally administered once a day for 3 days from day 4 post-PNI, based on published studies [19]. DSP-4 (50 mg/kg, a NAergic neurotoxin) was intraperitoneally administered 3 days before PNI, based on published studies [20]. PCPA and DSP-4 were dissolved in saline.

Statistical analysis
Statistical analyses were performed using one-way ANOVA with Bonferroni’s multiple comparison test (Figs 1A–1B and 2), Student’s t test (Fig 3A–3B), one-way ANOVA with Bonferroni’s multiple comparison test (Figs 3C and 4A), Student’s t test (Fig 4B–4C), two-way ANOVA with post hoc Bonferroni test (Fig 5A) or one-way ANOVA with post hoc Tukey Multiple Comparison test (Fig 5B) using GraphPad Prism 4 software. Differences were considered significant at P < 0.05.

Results
Duloxetine inhibits function of recombinant P2X4R expressed in 1321N1 cells
We screened 1979 compounds to identify clinically approved drugs that inhibit P2X4R. Using a high-throughput Ca$^{2+}$ imaging apparatus, we measured [Ca$^{2+}$], levels in 1321N1 human astrocytoma cells (1321N1 cells) stably expressing rP2X4R (rP2X4R-1321N1) [13]. We identified the SNRI duloxetine as a compound that has an inhibitory effect on ATP-induced increases in [Ca$^{2+}$], and that is known to possess both oral availability and the ability to cross the blood-brain barrier. The inhibitory effect of duloxetine was concentration dependent in rP2X4R-1321N1 cells (Fig 1A). In Ca$^{2+}$ imaging analysis at the single cell level using hP2X4R-1321N1 cells, duloxetine produced similar inhibitory effects, with an IC$_{50}$ value of 1.59 μM (Fig 1B). These results indicate that duloxetine has an inhibitory effect on recombinant rat and human P2X4R.
Fig 1. Duloxetine inhibits function of recombinant P2X4R. (A) Effects of duloxetine (3–30 μM) and PPADS (10 μM) on ATP (10 μM)-induced [Ca^{2+}]_i responses in rP2X4R-1321N1 cells measured by the FDSS 7000EX system. Each column indicates the value as a percentage of control (Ctl: 10 μM ATP alone-induced [Ca^{2+}]_i responses) (n = 4, ***P < 0.001 vs. control). (B) Effect of duloxetine at various concentrations (1–10 μM) on ATP (10 μM)-induced [Ca^{2+}]_i responses in hP2X4R-1321N1 cells measured at a single cell level. Each column shows the effect of duloxetine evaluated by the S2 (2nd [Ca^{2+}]_i response) / S1 (1st [Ca^{2+}]_i response) (n = 4, ***P < 0.001 vs. control).
We also tested two other antidepressants categorized into different classes that had not been previously tested, mirtazapine (NAergic and specific 5-HTergic antidepressant) and bupropion (NA-dopamine reuptake inhibitor). However, these two antidepressants at 30 μM had no effect on the ATP-evoked [Ca$^{2+}$]$_i$ responses in rP2X4R-1321N1 cells (Fig 2). In agreement with previous reports [13,21], paroxetine, maprotiline, clomipramine and amitriptyline significantly inhibited rat P2X4R-mediated [Ca$^{2+}$]$_i$ responses, and the inhibition by duloxetine was similar to that of paroxetine (Fig 2).

Duloxetine inhibited microglial P2X4R function

In the central nervous system, microglia predominantly express P2X4R. Therefore, we examined the effect of duloxetine using C8-B4 cells, a cell line of immortalized mouse cerebellar microglial cells. We found that duloxetine reduced the ATP-induced [Ca$^{2+}$]$_i$ increase (Fig 3A).
Fig 3. Duloxetine inhibited microglial P2X4R function. (A) Representative average traces of $[Ca^{2+}]_i$ increases in response to ATP (100 μM for 30 s) with or without duloxetine (30 μM for 10 min) measured by a single cell analysis in C8-B4 cells. Each column shows the effect of duloxetine evaluated by the S2 (2nd $[Ca^{2+}]_i$ response) / S1 (1st $[Ca^{2+}]_i$ response) (n = 4, ***P < 0.001 vs. control). (B) Representative average traces of $[Ca^{2+}]_i$ increases in response to ATP (50 μM for 30 s) with or without duloxetine (30 μM for 10 min) measured by single cell analysis in rat microglial cells. Each column shows the relative increase ratio.
We then assessed its effect in rat primary cultured microglial cells that endogenously express P2X4R \[4,15\]. Duloxetine (30 μM) significantly reduced the ATP-evoked $[\text{Ca}^{2+}]_i$ responses in microglial cells (Fig 3B). To selectively detect a P2X4R-mediated component, we co-applied ATP with macrocyclic lactone antibiotic ivermectin, which is a positive allosteric modulator specific for P2X4R \[22\]. Consistent with previous studies, ivermectin enhanced the ATP-induced $[\text{Ca}^{2+}]_i$, responses (Fig 3C). This enhancement was almost completely suppressed by duloxetine (30 μM) (Fig 3C), suggesting an inhibitory effect of duloxetine on endogenous P2X4R.

In addition to P2X4R, microglia express P2X7 receptors \[23\]. However, duloxetine (30 μM) had no effect on rP2X7R expressed in 1321N1 cells (Fig 4A). In rat primary cultured microglia, duloxetine (30 μM) had no effect on $[\text{Ca}^{2+}]_i$ responses evoked by BzATP, an agonist for P2X7R (Fig 4B). Microglia also respond to ADP via P2Y12 receptors (P2Y12R), a subtype that is crucial for the motility of microglial processes \[24\]. ADP evoked $[\text{Ca}^{2+}]_i$ responses, which were slightly, but significantly, reduced by duloxetine (Fig 4C). Taken together, these results suggest that duloxetine likely has an effect that is more selective to P2X4R.

Intrathecal administration of duloxetine attenuates mechanical allodynia after PNI: a possible involvement of P2X4R

Our previous studies have implicated microglial P2X4R in mechanical allodynia after PNI \[4,6,7,9,25,26\]; therefore, we next investigated whether duloxetine has an antiallodynic effect. After PNI, the paw withdrawal threshold to mechanical stimulation markedly decreased, implying the development of mechanical allodynia. After intrathecally administered duloxetine (20 or 50 μg) to rats on day 7 post-PNI, we found that the decreased paw withdrawal threshold was significantly reversed (Fig 5A): at 180 min, 48% (20 μg) and 57% (50 μg) recovery of paw withdrawal threshold (Fig 5B). Furthermore, we examined the antiallodynic effect of duloxetine in rats that had been pretreated with PCPA to deplete 5-HT, and with DSP-4 to produce a toxic effect on NAergic neurons that fully depletes 5-HT and NA \[20,27,28,29\]. In these PCPA- and DSP-4-pretreated rats, we found that the reversal effect of intrathecal duloxetine on the PNI-induced allodynia (Fig 5A): at 180 min after the injection of duloxetine, the pretreatment with PCPA and DSP-4 suppressed the duloxetine's effect (P < 0.05 and 0.01; Fig 5B). However, the antiallodynic effect of duloxetine still remained at a statistically significant level (Fig 5A and 5B). These results suggest it is possible that an antiallodynic effect of duloxetine in our model of neuropathic pain may be associated, at least in part, with its inhibitory effect on P2X4R.

Discussion

Our screening of clinically approved drugs revealed for the first time that the SNRI duloxetine has an inhibitory effect on P2X4R. We and others have previously reported that some antidepressants inhibit P2X4R-mediated $\text{Ca}^{2+}$ responses \[13,21,30\]; in this study, the IC$_{50}$ value of duloxetine for hP2X4R was 1.59 μM. This indicates duloxetine is as potent as paroxetine, which previously found to be the antidepressant with the most potent inhibition of P2X4R.
Fig 4. Effect of duloxetine on other P2 receptors. (A) Effect of duloxetine at various concentrations (3–30 μM) and PPADS (10 μM) on BzATP (100 μM)-induced [Ca^{2+}]_{i} responses in rP2X7R-1321N1 cells measured by the FDSS 7000EX system. Each column shows the value as a percentage of control (100 μM BzATP alone-induced [Ca^{2+}]_{i} responses) (n = 4). (B, C) Effects of duloxetine (30 μM) on [Ca^{2+}]_{i} responses induced by BzATP (100 μM) (B) and ADP (10 μM) (C) measured by a single cell analysis in primary cultured rat microglial cells. Each column shows the relative increase ratio (F340/F380) from the basal level prior to
Furthermore, at the concentration range eliciting P2X4R inhibition, duloxetine had no effect on P2X7R. This is in contrast to paroxetine which also inhibits P2X7R [13,31]. The tricyclic antidepressant amitriptyline has been reported to inhibit rat and mouse, but not human P2X4R [21]; in this study, the inhibitory effect of duloxetine was observed in rodent and human P2X4R, indicating the inhibition is not restricted to a specific species. Moreover, the P2X4R inhibition by duloxetine is not restricted to recombinant P2X4R. In our experiments, we showed the ability of duloxetine to inhibit P2X4R endogenously expressed in primary cultured microglial cells. It is well-known that microglia express several P2 receptors in addition to P2X4R [23], but by using ivermectin, a positive allosteric modulator specific for P2X4R [22], we showed a marked inhibition of P2X4R-mediated response by duloxetine. These results together indicate that duloxetine has an inhibitory effect on P2X4R expressed in microglial cells.

Studies have shown that duloxetine has attenuating effects on pain hypersensitivity in models of neuropathic pain associated with traumatic nerve injury [32,33,34,35], diabetic neuropathy [36,37] and fibromyalgia [38]. In addition to its clinical use for depression, duloxetine is frequently used for treating chronic pain such as diabetic neuropathic pain [39,40], chronic low back pain [41,42], osteoarthritis [41,43] and fibromyalgia [41,44,45]. It has been considered that the mechanism for pain relief by duloxetine might be distinct from its effect on depression [46]. The primary action of duloxetine is inhibition of 5-HT and NA reuptake into presynaptic terminals by their respective transporters. Thus, it is thought that the attenuating effects of duloxetine on neuropathic pain are related to an increase in the levels of 5-HT and NA in the descending pain inhibitory pathways from brainstem to the spinal dorsal horn [47,48]. Indeed, it has been reported that alleviation of mechanical allodynia in model of neuropathic pain by duloxetine was reduced by an intrathecal injection of a 5-HT_{2A} receptor antagonist [36,49] or by an intraperitoneally injection of DSP-4 to produce a toxic effect on NAergic neurons [20]. Consistent with these findings, the present study showed that the suppressing effect of duloxetine on PNI-induced allodynia was reduced in rats that had been pretreated with PCPA and DSP-4, at the dose of these agents needed to fully deplete 5-HT and NA [20,27]. However, the antiallodynic effect of intrathecal duloxetine still remained in the rats treated with both PCPA and DSP-4. Thus, it is possible that, in addition to the primary pharmacological action of duloxetine to inhibit 5-HT and NA transporters, an inhibitory effect on microglial P2X4R in the spinal cord may be involved in the antiallodynic effect of duloxetine when administered intrathecally in a model of neuropathic pain. In support of this idea, we previously demonstrated that expression of the P2X4R is upregulated exclusively in microglia in the spinal cord after PNI and that pharmacological blockade and molecular knockdown of the P2X4R produces a reversal of mechanical allodynia [4]. P2X4R-deficient mice also display a marked suppression of the PNI-induced mechanical allodynia [9,10]. Furthermore, intrathecal administration of paroxetine and fluvoxamine, which inhibits P2X4R, also produces a similar reversal of the PNI-induced allodynia, but citalopram, a SSRI that has no effect on P2X4R, does not suppress the allodynia [13]. Thus, these data support our hypothesis that an antiallodynic effect of duloxetine may be associated, at least in part, with its inhibitory effect on P2X4R.

In models of neuropathic pain, expression of P2X7R and P2Y12R are also increased in spinal microglia, and pharmacological blockade and genetic knockout of these receptors reduces pain hypersensitivities after PNI [50,51,52,53,54,55,56]. In this study, we observed that...
Fig 5. Intrathecal duloxetine attenuates allodynia after PNI: possible involvement of P2X4R. (A) The paw withdrawal threshold (grams) of mechanical stimulation by von Frey filaments applied to the rat hindpaw after PNI. Duloxetine (20 or 50 μg/20 μl) or vehicle (Phosphate buffered saline, 20 μl) was intrathecally administered to rats on day 7 post-PNI. PCPA (300 mg/kg, i.p.) was administered once a day for 3 days from day 4 post-PNI, and DSP-4 (50 mg/kg, i.p.) was administered 3 days before PNI. The threshold was measured 300 min after duloxetine injection (n = 5–13, **P < 0.01, ***P < 0.001). Data represent mean ± SEM. (B) The antiallodynic...
Duloxetine had no effect on P2X7R, and produced a weak inhibition of the ADP-induced 
$[Ca^{2+}]_{i}$ responses in primary cultured microglial cells, which might be mediated by P2Y12R. 
Thus, it is possible that intrathecally administered duloxetine may slightly attenuate P2Y12R 
function in spinal microglia, which may also be involved, at least in part, in duloxetine's effect 
on mechanical allodynia after PNI.

Conclusions

In this study, we provide evidence for the first time that the SNRI duloxetine has an inhibitory 
effect on recombinant P2X4R (rat and human) and microglial P2X4R (mouse and rat). Fur-
thermore, intrathecally administered duloxetine produced a reversal of mechanical alldynia,
and the effect was reduced but still remained in rats pretreated with both a 5-HT depleting 
agent and a NAergic neurotoxin. Thus, we hypothesized that, in addition to the primary action 
of duloxetine on monoamine transporters, inhibition of P2X4R may be involved in duloxe-
tine's antiallodynic effect in a model of neuropathic pain.

Acknowledgments

This work was supported by a research grant from Eli Lilly Japan (M.T.), Platform for Drug 
Discovery, Informatics, and Structural Life Science from Japan Agency for Medical Research 
and Development (AMED) (K.I.), the Research Project on Elucidation of Chronic Pain from 
AMED (M.T.). The funders had no role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript.

Author Contributions

Conceptualization: MT.
Formal analysis: TY SY.
Funding acquisition: MT KI.
Investigation: TY SY JZ MK DT KK HTS.
Methodology: TY SY.
Project administration: MT KI.
Supervision: KI MT.
Visualization: TY SY.
Writing – original draft: TY.
Writing – review & editing: TY MT KI.

References

1. Nightingale S (2012) The neuropathic pain market. Nat Rev Drug Discov 11: 101–102. doi: 10.1038/ 
rrd3624 PMID: 22293560
2. O’Connor AB, Dworkin RH (2009) Treatment of neuropathic pain: an overview of recent guidelines. 
Am J Med 122: S22–32.
3. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312–318. PMID: 8843599
4. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, et al. (2003) P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424: 778–783. doi: 10.1038/nature01786 PMID: 1291766
5. Tsuda M, Masuda T, Kitano J, Shimoyama H, Tozaki-Saitoh H, et al. (2009) IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc Natl Acad Sci U S A 106: 8032–8037. doi: 10.1073/pnas.0810420106 PMID: 19380717
6. Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, et al. (2012) IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Rep 1: 334–340. doi: 10.1016/j.celrep.2012.02.014 PMID: 22832225
7. Masuda T, Iwamoto S, Yoshinaga R, Tozaki-Saitoh H, Nishiyma A, et al. (2014) Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain. Nat Commun 5: 3771. doi: 10.1038/ncomms4771 PMID: 24818655
8. Guan Z, Kuhn JA, Wang X, Colquitt B, Solorzano C, et al. (2016) Injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent pain. Nat Neurosci 19: 94–101. doi: 10.1038/nn.4189 PMID: 26642091
9. Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, et al. (2009) Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays. Mol Pain 5: 28. doi: 10.1186/1744-8069-5-28 PMID: 19515262
10. Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, et al. (2008) Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci 28: 11263–11268. doi: 10.1523/JNEUROSCI.2308-08.2008 PMID: 18971468
11. Beggs S, Trang T, Salter MW (2012) P2X4R+ microglia drive neuropathic pain. Nat Neurosci 15: 1068–1073. doi: 10.1038/nn.3155 PMID: 22837036
12. Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K (2013) P2X4 receptors and neuropathic pain. Front Cell Neurosci 7: 191. doi: 10.3389/fncel.2013.00191 PMID: 24191146
13. Nagata K, Imai T, Yamashita T, Tsuda M, Tozaki-Saitoh H, et al. (2009) Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. Mol Pain 5: 20. doi: 10.1186/1744-8069-5-20 PMID: 19389225
14. Nakajima K, Shimojo M, Hanamoue M, Ishiura S, Sugita H, et al. (1992) Identification of elastase as a secretory protease from cultured rat microglia. J Neurochem 58: 1401–1408. PMID: 15454744
15. Toyomitsu E, Tsuda M, Yamashita T, Tozaki-Saitoh H, Tanaka Y, et al. (2012) CCL2 promotes P2X4 receptor trafficking to the cell surface of microglia. Purinergic Signal.
16. Matsushita K, Tozaki-Saitoh H, Kojima C, Masuda T, Tsuda M, et al. (2014) Chemokine (C-C motif) receptor 5 is an important pathological regulator in the development and maintenance of neuropathic pain. Anesthesiology 120: 1491–1503. doi: 10.1097/ALN.0000000000000190 PMID: 24589480
17. Kim SH, Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355–363. PMID: 1333581
18. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 53–63. PMID: 7990513
19. Ugedo L, Grenhoff J, Svensson TH (1989) Ritanerpin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 98: 45–50.
20. Kinoshita J, Takahashi Y, Watabe AM, Utsunomiya K, Kato F (2013) Impaired noradrenaline homeostasis in rats with painful diabetic neuropathy as a target of duloxetine analgesia. Mol Pain 9: 59. doi: 10.1186/1744-8069-9-59 PMID: 24279796
21. Sim JA, North RA (2010) Amitriptyline does not block the action of ATP at human P2X4 receptor. Br J Pharmacol 160: 88–92. doi: 10.1111/j.1476-5381.2010.06633.x PMID: 20331601
22. Khakh B, Proctor W, Dunwiddie T, Labarca C, Lester H (1999) Allosteric control of gating and kinetics at P2X(4) receptor channels. The Journal of neuroscience: the official journal of the Society for Neuroscience 19: 7289–7299.
23. Burnstock G (2008) Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7: 575–590. doi: 10.1038/nrd2605 PMID: 18591979
24. Haynes SE, Hollopete G, Yang G, Kurpius D, Dailey ME, et al. (2006) The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 9: 1512–1519. doi: 10.1038/nn1805 PMID: 17115040
25. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, et al. (2005) BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438: 1017–1021. doi: 10.1038/nature04223 PMID: 16355225

26. Biber K, Tsuda M, Tozaki-Saitoh H, Tsukamoto K, Toyomitsu E, et al. (2011) Neuronal CCL21 up-regulates microglia P2X4 expression and initiates neuropathic pain development. EMBO J 30: 1864–1873. doi: 10.1038/emboj.2011.89 PMID: 21441897

27. Kornum BR, Licht CL, Weikop P, Knudsen GM, Aznar S (2006) Central serotonin depletion affects rat brain areas differently: a qualitative and quantitative comparison between different treatment schemes. Neurosci Lett 392: 129–134. doi: 10.1016/j.neulet.2005.09.013 PMID: 16213658

28. Ross SB (1976) Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Br J Pharmacol 58: 521–527. PMID: 1000130

29. Koe BK, Weissman A (1966) p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther 154: 499–516. PMID: 5297133

30. Toulme E, Garcia A, Samways D, Egan T, Carson M, et al. (2010) P2X4 receptors in activated C8-B4 cells of cerebellar microglial origin. The Journal of general physiology 135: 333–353. doi: 10.1085/jgp.200910336 PMID: 20231374

31. Dao-Ung P, Skarratt KK, Fuller SJ, Stokes L (2015) Paroxetine suppresses recombinant human P2X7 responses. Purinergic Signal 11: 481–490. doi: 10.1007/s11302-015-9467-2 PMID: 26341077

32. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM (2004) Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311: 576–584. doi: 10.1124/jpet.104.070656 PMID: 15254142

33. Kiso T, Watabiki T, Tsukamoto M, Okabe M, Kagami M, et al. (2008) Pharmacological characterization and gene expression profiling of an LS/L6 spinal nerve ligation model for neuropathic pain in mice. Neuroscience 153: 492–500. doi: 10.1016/j.neuroscience.2008.02.031 PMID: 18400411

34. Le Cudennec C, Castagne V (2014) Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine. Eur J Pharmacol 735: 17–25. doi: 10.1016/j.ejphar.2014.04.003 PMID: 24726848

35. Hoshino H, Obata H, Saito S (2015) Antihyperalgesic effect of duloxetine and amitriptyline in rats after peripheral nerve injury: Influence of descending noradrenergic plasticity. Neurosci Lett 602: 62–67. doi: 10.1016/j.neulet.2015.06.041 PMID: 26135544

36. Mixcoatl-Zecuatl T, Jolivalt CG (2011) A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. Br J Pharmacol 164: 159–169. doi: 10.1111/j.1476-5381.2011.01334.x PMID: 21410686

37. Kuhad A, Bishnoi M, Chopra K (2009) Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol 47: 193–197. PMID: 19405385

38. Nagakura Y, Oe T, Aoki T, Matsuoka N (2009) Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 146: 26–33. doi: 10.1016/j.pain.2009.05.024 PMID: 19646816

39. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (2005) Duloxetine vs. placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50: 2974–2984. doi: 10.1002/art.20485 PMID: 15457467

40. Bennett RM (2009) Fibromyalgia: a new treatment option for fibromyalgia. Nat Rev Rheumatol 5: 188–190. doi: 10.1038/nrrheum.2009.48 PMID: 19337282

41. Skljarevski V, Zhang S, Iyengar S, D’Souza D, Alaka K, et al. (2011) Efficacy of Duloxetine in Patients with Chronic Pain Conditions. Curr Drug Ther 6: 296–303. doi: 10.2174/157488511798109992 PMID: 22876216

42. Williamson OD, Sagman D, Bruins RH, Boulay LJ, Schacht A (2014) Antidepressants in the treatment for chronic low back pain: questioning the validity of meta-analyses. Pain Pract 14: E33–41. doi: 10.1111/papr.12119 PMID: 24460577

43. Wang ZY, Shi SY, Li SJ, Chen F, Chen H, et al. (2015) Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials. Pain Med 16: 1373–1385. doi: 10.1111/pme.12800 PMID: 26176791

44. Perahia DG, Pritchett YL, Desaih D, Raskin J (2006) Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 21: 311–317. doi: 10.1097/01.yic.0000224782.83287.3c PMID: 17012978
47. Stamford JA (1995) Descending control of pain. Br J Anaesth 75: 217–227. PMID: 7577256
48. Smith T, Nicholson RA (2007) Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag 3: 833–844. PMID: 18200804
49. Sun YH, Li HS, Zhu C, Hu W, Yang J, et al. (2014) The analgesia effect of duloxetine on post-operative pain via intrathecal or intraperitoneal administration. Neurosci Lett 568: 6–11. doi: 10.1016/j.neulet.2014.03.046 PMID: 24686187
50. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, et al. (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114: 386–396. doi: 10.1016/j.pain.2005.01.002 PMID: 15777864
51. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, et al. (2006) A-740003 [N-(1-[(cyanomino)-(5-quinolinylamino)methyl]amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 319: 1376–1385. doi: 10.1124/jpet.106.111559 PMID: 16982702
52. Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Koehsaka S, et al. (2008) P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 28: 4949–4956. doi: 10.1523/JNEUROSCI.0323-08.2008 PMID: 18463248
53. Kobayashi K, Yamanaka H, Fukuoka T, Dai Y, Obata K, et al. (2008) P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain. J Neurosci 28: 2892–2902. doi: 10.1523/JNEUROSCI.5589-07.2008 PMID: 18337420
54. Kobayashi K, Takahashi E, Miyagawa Y, Yamanaka H, Noguchi K (2011) Induction of the P2X7 receptor in spinal microglia in a neuropathic pain model. Neurosci Lett 504: 57–61. doi: 10.1016/j.neulet.2011.08.058 PMID: 21924325
55. He WJ, Cui J, Du L, Zhao YD, Burnstock G, et al. (2012) Spinal P2X(7) receptor mediates microglia activation-induced neuropathic pain in the sciatic nerve injury rat model. Behav Brain Res 226: 163–170. doi: 10.1016/j.bbr.2011.09.015 PMID: 21933684
56. Xu J, Chen XM, Zheng BJ, Wang XR (2016) Electroacupuncture Relieves Nerve Injury-Induced Pain Hypersensitivity via the Inhibition of Spinal P2X7 Receptor-Positive Microglia. Anesth Analg 122: 882–892. doi: 10.1213/ANE.0000000000001097 PMID: 26599792